The Role of Traditional Chinese Medicine Natural Products in β-Amyloid Deposition and Tau Protein Hyperphosphorylation in Alzheimer’s Disease

References

• Academy of Cognitive Disorder of China, Writing Group of Expert Consensus on Long-term Healthcare of Cognitive Disorders in China. Chinese expert consensus on activity, behavior and cognition comprehensive management of Alzheimer’s disease. Chin J Geriatr. 2020;39(01):1–8. doi:10.3760/cma.j.issn.0254-9026.2020.01.001
   Google Scholar
• Lynch C. World Alzheimer Report 2019: attitudes to dementia, a global survey. Alzheimer’s & Dementia. 2020;16(S10):8255. doi:10.1002/alz.038255
   Google Scholar
• Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 2021;17(3):327–406. doi:10.1002/alz.12328
   PubMed Web of Science ®Google Scholar
• Chinese Society of Dementia and Cognitive Impairment. Chinese expert consensus on the diagnosis and treatment of mild cognitive impairment due to Alzheimer′s disease 2021. Chin J Neurol. 2022;55(5):421–440. doi:10.3760/cma.j.cn113694-20211004-00679
   Google Scholar
• Jia L, Du Y, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020;5(12):e661–e671. doi:10.1016/S2468-2667(20)30185-7
   PubMed Web of Science ®Google Scholar
• Wang WL, Song CS. Recent Advances in the Pathogenesis of Alzheimer′s Disease and Clinical Medication. Chin J Drug Eval. 2019;36(03):204–209. doi:10.3969/j.issn.2095-3593.2019.03.011
   Google Scholar
• Tian JZ, Xie HG, Wang LN, et al. the Guideline Panel of the Alzheimer’s Disease Chinese(ADC).Chinese guideline for the diagnosis and treatment of Alzheimer’s disease dementia(2020). Chin J Geriatr. 2021;40(3):269–283. doi:10.3760/cma.j.issn.0254-9026.2021.03.001
   Google Scholar
• Liu J, Wang LN, Tian JZ. Recognition of dementia in ancient China. Neurobiol Aging. 2012;33(12):2911–2948. doi:10.1016/j.neurobiolaging.2012.06.019
   Web of Science ®Google Scholar
• Zhang YG, Liang YQ, Li YL, et al. Talking about Alzheimer’s disease from ‘kidney deficiency phlegm stasis’ Evolution of TCM pathogenesis. Modernization Traditional Chin Med Mater Medica-World Sci Technol. 2021;23(01):159–164. doi:10.11842/wst.20200724001
   Google Scholar
• Tian JZ, Shi J, Ni JN, et al. Sequential Therapy Based on Evolvement of Patterns: a New Model for Treatment of Alzheimer’s Disease. Chin J Integr Med. 2019;25(8):565–573. doi:10.1007/s11655-019-3066-y
   PubMed Web of Science ®Google Scholar
• Tian J, Shi J, Wei M, et al. Chinese herbal medicine Qinggongshoutao for the treatment of amnestic mild cognitive impairment: a 52-week randomized controlled trial. Alzheimers Dement. 2019;5:441–449. doi:10.1016/j.trci.2019.03.001.eCollection2019
   Web of Science ®Google Scholar
• Savaskan E, Mueller H, Hoerr R, et al. Treatment effects of Ginkgo biloba extract EGb 761 on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials. Int Psychogeriatr. 2018;30(3):285–293. doi:10.1017/S1041610217001892
   PubMed Web of Science ®Google Scholar
• Shi J, Ni J, Lu T, et al. Adding Chinese herbal medicine to conventional therapy brings cognitive benefits to patients with Alzheimer’s disease: a retrospective analysis. BMC Complement Altern Med. 2017;17(1):533. doi:10.1186/s12906-017-2040-5
   PubMedGoogle Scholar
• Zhou XL. Research Progress of the Prevention and Treatment of Alzheimer’s Disease with Chinese Herbal Monomers and their Active Ingredients. World Latest Medi Inf. 2019;19(46):99–100.
   Google Scholar
• Cheng XR, Zhou WX, Zhang YX. Research on the pathogenesis of Alzheimer’s disease and prevention and treatment drugs. Chin J Pharmacol Toxicol. 2017;31(12):1129–1141. doi:10.3867/j.issn.1000-3002.2017.12.001
   Google Scholar
• Zhang YH, Yang MH, Wu DH. Research Progress of the Intervention of Monomer and Active Ingredients of Chinese Medicinal in Treatment of AD. Info Tradit Chin Med. 2019;36(03):118–122. doi:10.19656/j.cnki.1002-2406.190092
   Google Scholar
• Ryu JC, Zimmer ER, Rosa-Neto P, et al. Consequences of Metabolic Disruption in Alzheimer’s Disease Pathology. Neurotherapeutics. 2019;16(3):600–610. doi:10.1007/s13311-019-00755-y
   PubMed Web of Science ®Google Scholar
• Li C, Zhao L, Zang WD. Amyloid β-protein and neural network abnormality in Alzheimer’s disease. Chin Bull Life Sci. 2021;33(07):801–809. doi:10.13376/j.cbls/2021086
   Google Scholar
• Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595–608. doi:10.15252/emmm.201606210
   PubMed Web of Science ®Google Scholar
• Dunys J, Valverde A, Checler F. Are N- and C-terminally truncated Abeta species key pathological triggers in Alzheimer’s disease? J Biol Chem. 2018;293(40):15419–15428. doi:10.1074/jbc.R118.003999
   PubMed Web of Science ®Google Scholar
• Volloch V, Rits S. Results of Beta Secretase-Inhibitor Clinical Trials Support Amyloid Precursor Protein-Independent Generation of Beta Amyloid in Sporadic Alzheimer’s Disease. Med Sci. 2018;6(2). doi:10.3390/medsci6020045
   Google Scholar
• Li L, Xia BL, Ru LQ. Curative Effectiveness of Tanshinone in the Treatment of ModeI Rats with Two Kinds of Learning and Memory Impairment. Acta Med Univ Sei Technol Huazhong. 2008;37(06):819–822. doi:10.3870/j.issn.1672-0741.2008.06.031
   Google Scholar
• Zhuang Y, Shi B, Tian X, et al. Effects of ginsenoside Rg2 on learning and memory ability and senile plaque formation in rats with Alzheimer’s disease model. Chin J Gerontol. 2010;30(02):202–204. doi:10.3969/j.issn.1005-9202.2010.02.025
   Google Scholar
• Lu TT, Wang YY, Huang ZT, et al. The Influence of Berberine on Learning and Memory Ability and Amyloid Expression in APP/PS1 Transgenic Mice. Chin J Integr Med Cerebrovasc Dis. 2019;17(08):1155–1161.
   Google Scholar
• Niu K, Chen Y, Xiao YY, et al. Effect of β-asarone on the deposition of β-amyloid in the brain of AD mice. J Hefei Univ Technol, Nat Sci. 2022;45(04):561–564. doi:10.3969/j.issn.1003-5060.2022.04.022
   Google Scholar
• Xiao F, Luo HM, Li XG, et al. Inhibition of γ-schisandrin on the production of amyloid β-protein from M146L cells. Chin J New Drugs. 2005;1(3):290–292. doi:10.3321/j.issn:1003-3734.2005.03.010
   Google Scholar
• Li Z, Liu XC, Li R, et al. Reduction of Aβ Generation by Schisandrin B through Restraining Beta-Secretase 1 Transcription and Translation. Med Sci Monit. 2018;24:1219–1224. doi:10.12659/msm.905127
   PubMed Web of Science ®Google Scholar
• Chen Q, Gao CX, Ge LH. The Effect of Senegenin on Neuromorphopathological Changes of AD Rats with β-Amyloid1-40 Injection into Right. Nucleus Basalis Acta Laser Biol Sin. 2006;2006(3):294–298. doi:10.3389/fphar.2022.937333
   Google Scholar
• Webster B, Hansen L, Adame A, et al. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J Neuropathol Exp Neurol. 2006;65(2):142–151. doi:10.1097/01.jnen.0000199599.63204.6f
   PubMed Web of Science ®Google Scholar
• Qi H, Prabakaran S, Cantrelle FX, et al. Characterization of Neuronal Tau Protein as a Target of Extracellular Signal-regulated Kinase. J Biol Chem. 2016;291(14):7742–7753. doi:10.1074/jbc.M115.700914
   PubMed Web of Science ®Google Scholar
• Li SX, Han YS, Ji XY, et al. The Influence of Curcumin on the Expression of ERK Protein in Hippocampal Neurons Induced by Aβ in Rats with Alzheimer’s. Disease Acta Chin Med Pharmacol. 2014;42(02):21–23. doi:10.19664/j.cnki.1002-2392.2014.02.008
   Google Scholar
• Sun T, Zhang DS, Jing YS. Therapeutic effect of curcumin on Alzheimer’s disease and its mechanism. Chin J Pharmacol Toxicol. 2021;35(09):641.
   Google Scholar
• Ma YX, Jiao JL, Liu CY, et al. Effect of rhizoma acori graminei on the secondary structure of amyloid beta-protein 25-35. Chin J Pathophysiol. 2007;2:352–355. doi:10.3321/j.issn:1000-4718.2007.02.033
   Google Scholar
• Huang X, Liu G, Guo J, et al. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14(11):1483–1496. doi:10.7150/ijbs.27173
   PubMed Web of Science ®Google Scholar
• Xie Y, Shi X, Sheng K, et al. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia(Review). Mol Med Rep. 2019;19(2):783–791. doi:10.3892/mmr.2018.9713
   PubMed Web of Science ®Google Scholar
• Gabbouj S, Ryhanen S, Marttinen M, et al. Altered Insulin Signaling in Alzheimer’s Disease Brain - Special Emphasis on PI3K-Akt Pathway. Front Neurosci. 2019;13:629. doi:10.3389/fnins.2019.00629
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang Y, Li H, et al. Neuroprotective effects of salidroside through PI3K/Akt pathway activation in Alzheimer’s disease models. Drug Des Devel Ther. 2016;10:1335–1343. doi:10.2147/DDDT.S99958
   PubMed Web of Science ®Google Scholar
• Wang H, Li Q, Sun S, et al. Neuroprotective Effects of Salidroside in a Mouse Model of Alzheimer’s Disease. Cell Mol Neurobiol. 2020;40(7):1133–1142. doi:10.1007/s10571-020-00801-w
   PubMed Web of Science ®Google Scholar
• Guo B, Zhang W, Xu S, et al. GSK-3beta mediates dexamethasone-induced pancreatic beta cell apoptosis. Life Sci. 2016;144:1–7. doi:10.1016/j.lfs.2015.11.017
   PubMed Web of Science ®Google Scholar
• Luo CC, Yuan CY, Chen QF. GOLPH3 regulates proliferation and apoptosis of endometrial carcinoma cells through PI3K/AKT/GSK3βsignal. J Int Oncol. 2020;47(02):65–69. doi:10.3760/cma.j.issn.1673-422X.2020.02.001
   Google Scholar
• Sun XY, J LL, Dong QX, et al. Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer’s disease. J Neuroinflammation. 2021;18(1):131. doi:10.1186/s12974-021-02182-3
   PubMed Web of Science ®Google Scholar
• Ma GX, Ding QP, Deng HH, et al. Effect of astragalus polysaccharide and mechanism on Alzheimer’s disease rats. Stroke nerv dis. 2017;24(04):323–327. doi:10.3969/j.issn.1007-0478.2017.04.011
   Google Scholar
• Du J, Murphy RM. Characterization of the interaction of beta-amyloid with transthyretin monomers and tetramers. Biochemistry. 2010;49(38):8276–8289. doi:10.1021/bi101280t
   PubMed Web of Science ®Google Scholar
• Lin M, Wang M, Gao SQ, et al. Effect of resveratrol on cognitive function and the expression of Aβ1-40 and Aβ1-42 in cerebral cortex of model mice with Alzheimer’s disease. J Mod Med Health. 2017;33(16):2425–2427. doi:10.3969/j.issn.1009-5519.2017.16.006
   Google Scholar
• Santos LM, Rodrigues D, Alemi M, et al. Resveratrol administration increases Transthyretin protein levels ameliorating AD features- importance of transthyretin tetrameric stability. Mol Med. 2016;22:597–607. doi:10.2119/molmed.2016.00124
   PubMed Web of Science ®Google Scholar
• Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998;19(5):608–624. doi:10.1210/edrv.19.5.0349
   PubMed Web of Science ®Google Scholar
• Son SM, Cha MY, Choi H, et al. Insulin-degrading enzyme secretion from astrocytes is mediated by an autophagy-based unconventional secretory pathway in Alzheimer disease. Autophagy. 2016;12(5):784–800. doi:10.1080/15548627.2016.1159375
   PubMed Web of Science ®Google Scholar
• Vekrellis K, Ye Z, Qiu WQ, et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 2000;20(5):1657–1665. doi:10.1523/JNEUROSCI.20-05-01657.2000
   PubMed Web of Science ®Google Scholar
• Jha NK, Jha SK, Kumar D, et al. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer’s Disease Biology: characterization of Putative Cognates for Therapeutic Applications. J Alzheimers Dis. 2015;48(4):891–917. doi:10.3233/JAD-150379
   PubMed Web of Science ®Google Scholar
• Lei DL, Li MB, Xiong K, et al. Triptolide inhibits the Aβ deposition and senile plaques formation in the hippocampus of APP/PS1 double transgenic mice. Acta Anat Sin. 2009;40(03):369–373. doi:10.3969/j.issn.0529-1356.2009.03.005
   Google Scholar
• Cheng S, Leblanc KJ, Li L. Triptolide preserves cognitive function and reduces neuropathology in a mouse model of Alzheimer’s disease. PLoS One. 2014;9(9):e108845. doi:10.1371/journal.pone.0108845
   PubMedGoogle Scholar
• Wang Q, Xiao B, Cui S, et al. Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD. Dis Model Mech. 2014;7(12):1385–1395. doi:10.1242/dmm.018218
   PubMed Web of Science ®Google Scholar
• Huang JL, Feng YQ, Bai LR, et al. Fraction n-Butanol of Radix Notoginseng Protects PC12 Cells from Abeta(25-35)-Induced Cytotoxicity and Alleviates Cognitive Deficits in SAMP8 Mice by Attenuating Oxidative Stress and Abeta Accumulation. Evid Based Complement Alternat Med. 2017;2017:8469754. doi:10.1155/2017/8469754
   PubMed Web of Science ®Google Scholar
• Jin K, Peel AL, Mao XO, et al. Increased hippocampal neurogenesis in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2004;101(1):343–347. doi:10.1073/pnas.2634794100
   PubMed Web of Science ®Google Scholar
• Liu CY, Zhang PX, Rong GY, et al. Effects of tetramethylpyrazine on the expression of APP and NEP in the brain of rats with Alzheimer’s disease (AD) model. Heiilongjiang Medi Pharm. 2016;39(03):8–9. doi:10.3969/j.issn.1008-0104.2016.03.004
   Google Scholar
• Liu SZ, Cheng W, Shao JW, et al. Notoginseng Saponin Rg1 Prevents Cognitive Impairment through Modulating APP Processing in Abeta(1-42)-injected Rats. Curr Med Sci. 2019;39(2):196–203. doi:10.1007/s11596-019-2019-1
   PubMed Web of Science ®Google Scholar
• Moreno-Jimenez EP, Flor-Garcia M, Terreros-Roncal J, et al. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer’s disease. Nat Med. 2019;25(4):554–560. doi:10.1038/s41591-019-0375-9
   PubMed Web of Science ®Google Scholar
• Erlandsson A, Lin CH, Yu F, et al. Immunosuppression promotes endogenous neural stem and progenitor cell migration and tissue regeneration after ischemic injury. Exp Neurol. 2011;230(1):48–57. doi:10.1016/j.expneurol.2010.05.018
   PubMed Web of Science ®Google Scholar
• Kolb B, Morshead C, Gonzalez C, et al. Growth factor-stimulated generation of new cortical tissue and functional recovery after stroke damage to the motor cortex of rats. J Cereb Blood Flow Metab. 2007;27(5):983–997. doi:10.1038/sj.jcbfm.9600402
   PubMed Web of Science ®Google Scholar
• Jin K, Galvan V, Xie L, et al. Enhanced neurogenesis in Alzheimer’s disease transgenic (PDGF-APPSw, Ind) mice. Proc Natl Acad Sci U S A. 2004;101(36):13363–13367. doi:10.1073/pnas.0403678101
   PubMed Web of Science ®Google Scholar
• Niidome T, Taniuchi N, Akaike A, et al. Differential regulation of neurogenesis in two neurogenic regions of APPswe/PS1dE9 transgenic mice. Neuroreport. 2008;19(14):1361–1364. doi:10.1097/WNR.0b013e32830e6dd6
   PubMed Web of Science ®Google Scholar
• Rodriguez JJ, Jones VC, Tabuchi M, et al. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer’s disease. PLoS One. 2008;3(8):e2935. doi:10.1371/journal.pone.0002935
   PubMed Web of Science ®Google Scholar
• Cheung WM, Hui WS, Chu PW, et al. Ganoderma extract activates MAP kinases and induces the neuronal differentiation of rat pheochromocytoma PC12 cells. FEBS Lett. 2000;486(3):291–296. doi:10.1016/s0014-5793(00)02317-6
   PubMed Web of Science ®Google Scholar
• Chu QP, Wang LE, Cui XY, et al. Extract of Ganoderma lucidum potentiates pentobarbital-induced sleep via a GABAergic mechanism. Pharmacol Biochem Behav. 2007;86(4):693–698. doi:10.1016/j.pbb.2007.02.015
   PubMed Web of Science ®Google Scholar
• Matsuzaki H, Shimizu Y, Iwata N, et al. Antidepressant-like effects of a water-soluble extract from the culture medium of Ganoderma lucidum mycelia in rats. BMC Complement Altern Med. 2013;13:370. doi:10.1186/1472-6882-13-370
   PubMed Web of Science ®Google Scholar
• Qin C, Wu SQ, Chen BS, et al. Pathological Changes in APP/PS-1 Transgenic Mouse Models of Alzheimer’s Disease Treated with Ganoderma lucidum Preparation. Acta Acad Med Sin. 2017;39(4):552–561. doi:10.3881/j.issn.1000-503X.2017.04.015
   Google Scholar
• Huang S, Mao J, Ding K, et al. Polysaccharides from Ganoderma lucidum Promote Cognitive Function and Neural Progenitor Proliferation in Mouse Model of Alzheimer’s Disease. Stem Cell Reports. 2017;8(1):84–94. doi:10.1016/j.stemcr.2016.12.007
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang L, Yuan X, et al. The Relationship between the Bcl-2/Bax Proteins and the Mitochondria-Mediated Apoptosis Pathway in the Differentiation of Adipose-Derived Stromal Cells into Neurons. PLoS One. 2016;11(10):e163327. doi:10.1371/journal.pone.0163327
   PubMed Web of Science ®Google Scholar
• Wang C, Yao B, Xu M, et al. RIP1 upregulation promoted tumor progression by activating AKT/Bcl-2/BAX signaling and predicted poor postsurgical prognosis in HCC. Tumour Biol. 2016;37(11):15305–15313. doi:10.1007/s13277-016-5342-1
   PubMedGoogle Scholar
• Saito A, Suga K, Ono-Nakagawa R, et al. Time lapse imaging analysis of the effect of ER stress modulators on apoptotic cell assessed by caspase3/7 activation in NG108-15 cells. Data Brief. 2016;6:20–27. doi:10.1016/j.dib.2015.11.030
   PubMedGoogle Scholar
• Liu ZZ, Fu X, Chen G, et al. Combined effects and mechanism of lactate dehydrogenase A gene knockout and mitomycin C on prostate cancer cell apoptosis. Chin J Biomed Eng. 2016;22(3):206–209. doi:10.3760/cma.j.issn.1674-1927.2016.03.006
   Google Scholar
• Mitupatum T, Aree K, Kittisenachai S, et al. mRNA Expression of Bax, Bcl-2, p53, Cathepsin B, Caspase-3 and Caspase-9 in the HepG2 Cell Line Following Induction by a Novel Monoclonal Ab Hep88 mAb: cross-Talk for Paraptosis and Apoptosis. Asian Pac J Cancer Prev. 2016;17(2):703–712. doi:10.7314/apjcp.2016.17.2.703
   PubMedGoogle Scholar
• Liu C, Wang Y, Wang JY, et al. Expression of Bax on beta-amyloid (Aβ) -induced PC12 cell by Anemarrhena total saponins. Chin J Gerontol. 2014;34(18):5163–5165. doi:10.3969/j.issn.1005-9202.2014.18.68
   Google Scholar
• Yin G, Gong DK, Liu BH, et al. Effects of Cistanche polysaccharide on learning and memory ability and expression of Bcl-2 and caspase-3 in hippocampal neurons of rats with Alzheimer’s disease. Lishizhen Med Mater Med Res. 2013;24(05):1091–1092. doi:10.3969/j.issn.1008-0805.2013.05.027
   Google Scholar
• Luo L, Wang XW, Shi KR, et al. Preliminary study on the pathomorphology of the Glycosides of Cistanche Herba on the hippocampal CA1 area of experimental AD rats induced by β-amyloid. J North Sichuan Med Coll. 2020;35(06):947–951. doi:10.3969/j.issn.1005-3697.2020.06.02
   Google Scholar
• Xiao F, Li XG, Gao Q, et al. The inhibition of amyloid β-protein production in M146L cell by Kadsura heteroclita polysaccharide. Chin J Gerontol. 2009;29(19):2458–2460. doi:10.3969/j.issn.1005-9202.2009.19.017
   Google Scholar
• Xue JC. Effects of wogonoside on the nerves of APP/PS1 double transgenic mice neuroprotection and its mechanism. Guang zhou: Guangzhou University of Chinese Medicine; 2021. doi:10.27044/d.cnki.ggzzu.2021.001040
   Google Scholar
• Hu XY, Sun XQ, Li ZP. Protective effect of phillyrin on HT22 cells and APP/PS1 mice induced by L-glutamate. Chin J Gerontol. 2022;42(07):1710–1714. doi:10.3969/j.issn.1005-9202.2022.07.051
   Google Scholar
• Tayler H, Miners JS, Guzel O, et al. Mediators of cerebral hypoperfusion and blood-brain barrier leakiness in Alzheimer’s disease, vascular dementia and mixed dementia. Brain Pathol. 2021;31(4):e12935. doi:10.1111/bpa.12935
   PubMed Web of Science ®Google Scholar
• He Y, Ruganzu JB, Zheng Q, et al. Silencing of LRP1 Exacerbates Inflammatory Response Via TLR4/NF-kappaB/MAPKs Signaling Pathways in APP/PS1 Transgenic Mice. Mol Neurobiol. 2020;57(9):3727–3743. doi:10.1007/s12035-020-01982-7
   PubMed Web of Science ®Google Scholar
• Aurelie N. LRP1 plays a major role in the amyloid-β clearance in microglia. Mol Neurodegener. 2013;8:S1. doi:10.1186/1750-1326-8-S1-P33
   PubMedGoogle Scholar
• Pascale CL, Miller MC, Chiu C, et al. Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids Barriers CNS. 2011;8:21. doi:10.1186/2045-8118-8-21
   PubMedGoogle Scholar
• Zhao XS. Effects and Mechanism of Ox-LDL on Neural Cells Apoptosis Mediated by PCSK9/LRP1. Hu Nan: University of South China; 2016.
   Google Scholar
• Chen HD. The Mechanism of the Aβ Clearance by Baicailin Through Blood Brain Barrier Pathwayin Alzheimer’s Disease Mouse. Guang zhou: Guang zhou university of chinese medicine; 2021. doi:10.27044/d.cnki.ggzzu.2021.001038
   Google Scholar
• Tang G, Tang X, Mendu V, et al. The art of microRNA: various strategies leading to gene silencing via an ancient pathway. Biochim Biophys Acta. 2008;1779(11):655–662. doi:10.1016/j.bbagrm.2008.06.006
   PubMed Web of Science ®Google Scholar
• Mcgeer PL, Mcgeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28(5):639–647. doi:10.1016/j.neurobiolaging.2006.03.013
   PubMed Web of Science ®Google Scholar
• Lin Y, Yao YJ, Liang XC, et al. Osthole suppresses BACE-1 expression by up-regulating miR-9 in Alzheimer’s disease. Chin Pharmacol Bull. 2019;35(04):524–529. doi:10.3969/j.issn.1001-1978.2019.04.016
   Google Scholar
• Canet G, Chevallier N, Zussy C, et al. Central Role of Glucocorticoid Receptors in Alzheimer’s Disease and Depression. Front Neurosci. 2018;12:739. doi:10.3389/fnins.2018.00739
   PubMed Web of Science ®Google Scholar
• Doody RS, Raman R, Farlow M, et al. A Phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369(4):341–350. doi:10.1056/NEJMoa1210951
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322–333. doi:10.1056/NEJMoa1304839
   PubMed Web of Science ®Google Scholar
• Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–321. doi:10.1056/NEJMoa1312889
   PubMed Web of Science ®Google Scholar
• Xia ZY, Zhao H, Pan LX, et al. Research progress on the role of Tau protein in Alzheimer’s disease. Neural Inj Functional Reconstruction. 2019;14(09):450–453. doi:10.16780/j.cnki.sjssgncj.2019.09.006
   Google Scholar
• Dai XY, Zhang LY, Ren J, et al. Effect of glutamate receptor antagonist on learning-memory impairment and protein Tau hyperphosphorylation in neonatal rats after fetal distress. Chin Med. 2016;11(11):1718–1723. doi:10.3760/cma.j.issn.1673-4777.2016.11.032
   Google Scholar
• Zhu ZP, Zhu H. Research progress in imaging agents targeting Aβ and Tau protein in Alzheimer′s disease. Chin J Nucl Med Mol Imaging. 2018;38(4):291–294. doi:10.3760/cma.j.issn.2095-2848.2018.04.018
   Google Scholar
• Stefanoska K, Gajwani M, Tan A, et al. Alzheimer’s disease: ablating single master site abolishes tau hyperphosphorylation. Sci Adv. 2022;8(27):l8809. doi:10.1126/sciadv.abl8809
   Web of Science ®Google Scholar
• Xu KL, Chen Q, Liu W, et al. Effect of senegenin on tau protein phosphorylation at Ser396 site in neurons of AD rats induced by Aβ1-40. Chin J Pathophysiol. 2012;28(09):1605–1609. doi:10.3969/j.issn.1000-4718.2012.09.012
   Google Scholar
• Ye J, Yin Y, Liu H, et al. Tau inhibits PKA by nuclear proteasome-dependent PKAR2alpha elevation with suppressed CREB/GluA1 phosphorylation. Aging Cell. 2020;19(1):e13055. doi:10.1111/acel.13055
   PubMed Web of Science ®Google Scholar
• Hu H, Liao ZD. Phosphorylation and dephosphorylation of tau protein in Alzheimer’s disease. Guang X Med J. 2010;32(05):602–605. doi:10.3969/j.issn.0253-4304.2010.05.043
   Google Scholar
• Trushina NI, Bakota L, Mulkidjanian AY, et al. The Evolution of Tau Phosphorylation and Interactions. Front Aging Neurosci. 2019;11:256. doi:10.3389/fnagi.2019.00256
   PubMed Web of Science ®Google Scholar
• Li X, Zhang X, Zhang ZY, et al. The effects of Gensenoside Rg1 on the expressions of P-Tau and PKA on the brain slices of AD model rats. Chin J Gerontol. 2009;29(19):2468–2470. doi:10.3969/j.issn.1005-9202.2009.19.021
   Google Scholar
• Li MZ, Wu WH, Wu ZP, et al. Panax Notoginseng Saponins Rg1 Improves Spatial Cognitive Ability and Decreases Phosphorylation Level of Tau Protein in Alzheimer’s Disease Rat Model. Acta Med Univ Sci Technol Huazhong. 2017;46(03):248–252. doi:10.3870/j.issn.1672-0741.2017.03.002
   Google Scholar
• Sun DM. Therapeutic effects of curcumin in mice with Alzheimer’s disease. Chin J Gerontol. 2019;39(18):4577–4580. doi:10.3969/j.issn.1005-9202.2019.18.063
   Google Scholar
• Wang H, Sui H, Zheng Y, et al. Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT/GSK-3beta pathway. Nanoscale. 2019;11(15):7481–7496. doi:10.1039/c9nr01255a
   PubMed Web of Science ®Google Scholar
• Metaxas A, Kempf SJ. Neurofibrillary tangles in Alzheimer’s disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics. Neural Regen Res. 2016;11(10):1579–1581. doi:10.4103/1673-5374.193234
   PubMed Web of Science ®Google Scholar
• Iqbal K, Gong CX, Liu F. Microtubule-associated protein tau as a therapeutic target in Alzheimer’s disease. Expert Opin Ther Targets. 2014;18(3):307–318. doi:10.1517/14728222.2014.870156
   PubMed Web of Science ®Google Scholar
• Yan HM, Du XB, Zhang JJ. Effect of Radix Angelica Sinensis on Alzheimer’s disease-like lesions and cognitive function in rats with chronic cerebral hypoperfusion. Chin J Geriatr Heart, Brain Vessel Dis. 2017;19(07):699–703. doi:10.3969/j.issn.1009-0126.2017.07.007
   Google Scholar
• Chen H, Lombes M, Le Menuet D. Glucocorticoid receptor represses brain-derived neurotrophic factor expression in neuron-like cells. Mol Brain. 2017;10(1):12. doi:10.1186/s13041-017-0295-x
   PubMedGoogle Scholar
• Riise J, Plath N, Pakkenberg B, et al. Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer’s disease. J Neural Transm. 2015;122(9):1303–1318. doi:10.1007/s00702-015-1375-7
   PubMed Web of Science ®Google Scholar
• Fiorentini A, Rosi MC, Grossi C, et al. Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS One. 2010;5(12):e14382. doi:10.1371/journal.pone.0014382
   PubMed Web of Science ®Google Scholar
• Kim SE, Huang H, Zhao M, et al. Wnt stabilization of beta-catenin reveals principles for morphogen receptor-scaffold assemblies. Science. 2013;340(6134):867–870. doi:10.1126/science.1232389
   PubMed Web of Science ®Google Scholar
• Willert K, Jones KA. Wnt signaling: is the party in the nucleus? Genes Dev. 2006;20(11):1394–1404. doi:10.1101/gad.1424006
   PubMed Web of Science ®Google Scholar
• Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149(6):1192–1205. doi:10.1016/j.cell.2012.05.012
   PubMed Web of Science ®Google Scholar
• Huo JT, Zhang XQ, Yan J, et al. Activation of Wnt signaling pathway by tetramethylpyrazine improves brain tissue inflammation in rats with Alzheimer’s disease. Zhejiang Clin Med J. 2015;2015(8):1262–1264.
   Google Scholar
• Yao HT, Ma JL, Zhang XB, et al. Effect of Cornus officinalis polysaccharide on tau protein in Alzheimer’s disease model rats. Chin J Gerontol. 2013;33(12):2838–2841. doi:10.3969/j.issn.1005-9202.2013.12.047
   Google Scholar
• Su YN, Yao HT, Zhang XB, et al. Effects of Cornus officinale polysaccharide on glycogen synthase kinase-3β and phosphorylated-tau protein in the hippocampus of rats with an Alzheimer’s disease model. Chin J Gerontol. 2017;37(12):2885–2887. doi:10.3969/j.issn.1005-9202.2017.12.010
   Google Scholar
• Li H, Liu C, Li N, et al. Improvement of acidic polysaccharose of Schisandra Chinensis on learning and memory functions of Alzheimer’s disease model mice. J Jilin Univ, Med Ed. 2017;43(06):1115–1120. doi:10.13481/j.1671-587x.20170609
   Google Scholar
• Ni YN, Wang MY, Kong L, et al. Effect of osthole on tau hyperphosphorylation and PI3K/Akt/Gsk3β signaling pathway in the brain of AD mice. Chin New Drugs J. 2019;28(23):2865–2871. doi:10.3969/j.issn.1003-3734.2019.23.013
   Google Scholar
• Lee MS, Kwon YT, Li M, et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405(6784):360–364. doi:10.1038/35012636
   PubMed Web of Science ®Google Scholar
• Patrick GN, Zukerberg L, Nikolic M, et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402(6762):615–622. doi:10.1038/45159
   PubMed Web of Science ®Google Scholar
• Alvarez A, Toro R, Caceres A, et al. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett. 1999;459(3):421–426. doi:10.1016/s0014-5793(99)01279-x
   PubMed Web of Science ®Google Scholar
• Shi LL, Yang WN, Chen XL, et al. The protective effects of tanshinone IIA on neurotoxicity induced by beta-amyloid protein through calpain and the p35/Cdk5 pathway in primary cortical neurons. Neurochem Int. 2012;61(2):227–235. doi:10.1016/j.neuint.2012.04.019
   PubMed Web of Science ®Google Scholar
• Lin L, Jadoon SS, Liu SZ, et al. Tanshinone IIA Ameliorates Spatial Learning and Memory Deficits by Inhibiting the Activity of ERK and GSK-3beta. J Geriatr Psychiatry Neurol. 2019;32(3):152–163. doi:10.1177/0891988719837373
   PubMed Web of Science ®Google Scholar
• Gong CX, Liu F, Grundke-Iqbal I, et al. Post-translational modifications of tau protein in Alzheimer’s disease. J Neural Transm. 2005;112(6):813–838. doi:10.1007/s00702-004-0221-0
   PubMed Web of Science ®Google Scholar
• Sanchez-Mut JV, Aso E, Heyn H, et al. Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer’s disease. Hippocampus. 2014;24(4):363–368. doi:10.1002/hipo.22245
   PubMed Web of Science ®Google Scholar
• Szegeczki V, Horvath G, Perenyi H, et al. Alzheimer’s Disease Mouse as a Model of Testis Degeneration. Int J Mol Sci. 2020;21(16). doi:10.3390/ijms21165726
   PubMed Web of Science ®Google Scholar
• Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, et al. PP2A mRNA expression is quantitatively decreased in Alzheimer’s disease hippocampus. Exp Neurol. 2001;168(2):402–412. doi:10.1006/exnr.2001.7630
   PubMed Web of Science ®Google Scholar
• Sontag JM, Sontag E. Protein phosphatase 2A dysfunction in Alzheimer’s disease. Front Mol Neurosci. 2014;7:548.
   Web of Science ®Google Scholar
• Chen Q, et al. Banqiao Codonopsis pilosula improves cognitive dysfunction in AD model rats by PP2A signaling pathway. Chin Pharmacol Bull. 2019;35:1232–1239. doi:10.3969/j.issn.1001-1978.2019.09.010
   Google Scholar
• Xie WZ. Trillium tschonoskii maxim improves cognitive dysfunction in Alzheimer’s disease induced by okadaic acid in rats and its possible mechanism. Chin Pharmacol Bull. 2018;34:1268–1275. doi:10.3969/j.issn.1001-1978.2018.09.017
   Google Scholar
• Ma D, et al. Cornel iridoid glycoside suppresses tau hyperphosphorylation and aggregation in a mouse model of tauopathy through increasing activity of PP2A. Curr Alzheimer Res. 2019;16:1316–1331. doi:10.2174/1567205017666200103113158
   PubMed Web of Science ®Google Scholar
• Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol. 2010;22(2):124–131. doi:10.1016/j.ceb.2009.11.014
   PubMed Web of Science ®Google Scholar
• Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983–997. doi:10.1038/nm.3232
   PubMed Web of Science ®Google Scholar
• Menzies FM, Fleming A, Rubinsztein DC. Compromised autophagy and neurodegenerative diseases. Nat Rev Neurosci. 2015;16(6):345–357. doi:10.1038/nrn3961
   PubMed Web of Science ®Google Scholar
• Menzies FM, Fleming A, Caricasole A, et al. Autophagy and Neurodegeneration: pathogenic Mechanisms and Therapeutic Opportunities. Neuron. 2017;93(5):1015–1034. doi:10.1016/j.neuron.2017.01.022
   PubMed Web of Science ®Google Scholar
• Kumar H, Kim IS, More SV, et al. Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases. Nat Prod Rep. 2014;31(1):109–139. doi:10.1039/c3np70065h
   PubMed Web of Science ®Google Scholar
• Mbaveng AT, Kuete V, Efferth T. Potential of Central, Eastern and Western Africa Medicinal Plants for Cancer Therapy: spotlight on Resistant Cells and Molecular Targets. Front Pharmacol. 2017;8:343. doi:10.3389/fphar.2017.00343
   PubMed Web of Science ®Google Scholar
• Pickford F, Masliah E, Britschgi M, et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest. 2008;118(6):2190–2199. doi:10.1172/JCI33585
   PubMed Web of Science ®Google Scholar
• Ni HM, Chao X, Yang H, et al. Dual Roles of Mammalian Target of Rapamycin in Regulating Liver Injury and Tumorigenesis in Autophagy-Defective Mouse Liver. Hepatology. 2019;70(6):2142–2155. doi:10.1002/hep.30770
   PubMed Web of Science ®Google Scholar
• Ni HM, Mcgill MR, Chao X, et al. Removal of Acetaminophen protein adducts by autophagy protects against Acetaminophen-induced liver injury in mice. J Hepatol. 2016;65(2):354–362. doi:10.1016/j.jhep.2016.04.025
   PubMed Web of Science ®Google Scholar
• Nilsson P, Loganathan K, Sekiguchi M, et al. Abeta secretion and plaque formation depend on autophagy. Cell Rep. 2013;5(1):61–69. doi:10.1016/j.celrep.2013.08.042
   PubMed Web of Science ®Google Scholar
• Nilsson P, Sekiguchi M, Akagi T, et al. Autophagy-related protein 7 deficiency in amyloid beta (Abeta) precursor protein transgenic mice decreases Abeta in the multivesicular bodies and induces Abeta accumulation in the Golgi. Am J Pathol. 2015;185(2):305–313. doi:10.1016/j.ajpath.2014.10.011
   PubMed Web of Science ®Google Scholar
• Uddin MS, Stachowiak A, Mamun AA, et al. Autophagy and Alzheimer’s Disease: from Molecular Mechanisms to Therapeutic Implications. Front Aging Neurosci. 2018;10:4. doi:10.3389/fnagi.2018.00004
   PubMed Web of Science ®Google Scholar
• Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy. 2007;3(6):542–545. doi:10.4161/auto.4600
   PubMed Web of Science ®Google Scholar
• Ohashi Y, Tremel S, Williams RL. VPS34 complexes from a structural perspective. J Lipid Res. 2019;60(2):229–241. doi:10.1194/jlr.R089490
   PubMed Web of Science ®Google Scholar
• Jaeger PA, Wyss-Coray T. Beclin 1 complex in autophagy and Alzheimer disease. Arch Neurol. 2010;67(10):1181–1184. doi:10.1001/archneurol.2010.258
   PubMedGoogle Scholar
• Zhou KY, Hu Y, Yang M, et al. Baicalin improves cognitive function by delaying senescence and regulating autophagy activity in Tau transgenic mice. Chin New Drugs J. 2019;28(01):65–72.
   Google Scholar
• Settembre C, Di malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036):1429–1433. doi:10.1126/science.1204592
   PubMed Web of Science ®Google Scholar
• Sardiello M, Palmieri M, Di Ronza A, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325(5939):473–477. doi:10.1126/science.1174447
   PubMed Web of Science ®Google Scholar
• Martina JA, Chen Y, Gucek M, et al. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy. 2012;8(6):903–914. doi:10.4161/auto.19653
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang Y, Liu A, et al. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells. Int J Mol Sci. 2016;17(4):531. doi:10.3390/ijms17040531
   PubMed Web of Science ®Google Scholar
• Polito VA, Li H, Martini-Stoica H, et al. Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB. EMBO Mol Med. 2014;6(9):1142–1160. doi:10.15252/emmm.201303671
   PubMed Web of Science ®Google Scholar
• Martini-Stoica H, Xu Y, Ballabio A, et al. The Autophagy-Lysosomal Pathway in Neurodegeneration: a TFEB Perspective. Trends Neurosci. 2016;39(4):221–234. doi:10.1016/j.tins.2016.02.002
   PubMed Web of Science ®Google Scholar
• Yang C, Su C, Iyaswamy A, et al. Celastrol enhances transcription factor EB (TFEB)-mediated autophagy and mitigates Tau pathology: implications for Alzheimer’s disease therapy. Acta Pharm Sin B. 2022;12(4):1707–1722. doi:10.1016/j.apsb.2022.01.017
   PubMed Web of Science ®Google Scholar
• Ferrari A, Hoerndli F, Baechi T, et al. beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem. 2003;278(41):40162–40168. doi:10.1074/jbc.M308243200
   PubMed Web of Science ®Google Scholar
• Götz J, Chen F, van Dorpe J, et al. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293(5534):1491–1495. doi:10.1126/science.1062097
   PubMed Web of Science ®Google Scholar
• Bolmont T, Clavaguera F, Meyer-Luehmann M, et al. Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol. 2007;171(6):2012–2020. doi:10.2353/ajpath.2007.070403
   PubMed Web of Science ®Google Scholar
• Desikan RS, McEvoy LK, Thompson WK, et al. Amyloid-beta associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011;70(4):657–661. doi:10.1002/ana.22509
   PubMed Web of Science ®Google Scholar
• Fortea J, Vilaplana E, Alcolea D, et al. Cerebrospinal fluid beta-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann Neurol. 2014;76(2):223–230. doi:10.1002/ana.24186
   PubMed Web of Science ®Google Scholar
• Busche MA, Hyman BT. Synergy between amyloid-beta and tau in Alzheimer’s disease. Nat Neurosci. 2020;23(10):1183–1193. doi:10.1038/s41593-020-0687-6
   PubMed Web of Science ®Google Scholar
• Hanseeuw BJ, Betensky RA, Schultz AP, et al. Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol. 2017;81(4):583–596. doi:10.1002/ana.24910
   PubMed Web of Science ®Google Scholar
• Perez-Nievas BG, Stein TD, Tai HC, et al. Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology. Brain. 2013;136(Pt 8):2510–2526. doi:10.1093/brain/awt171
   PubMedGoogle Scholar
• Prinz M, Jung S, Priller J. Microglia Biology: one Century of Evolving Concepts. Cell. 2019;179(2):292–311. doi:10.1016/j.cell.2019.08.053
   PubMed Web of Science ®Google Scholar
• Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337–351. doi:10.1016/j.neuron.2007.01.010
   PubMed Web of Science ®Google Scholar
• Zhang XL, Zeng JY, Chen X, et al. Comparison and Interpretation of Chinese and British Guidelines about Therapeutic Drugs for Alzheimer’s Disease. Chin Gen Pract. 2021;24(12):1454–1458. doi:10.12114/j.issn.1007-9572.2021.00.121
   Google Scholar
• Zhang HB, Xu Y, Chen B, et al. A meta-analysis of the prevalence of Alzheimer’s disease. Chin J Gerontol. 2018;38(9):2157–2162. doi:10.3969/j.issn.1005-9202.2018.09.045
   Google Scholar
• Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;13(1):80. doi:10.1186/s13195-021-00813-8
   PubMed Web of Science ®Google Scholar
• Wischik CM, Edwards PC, Lai RY, et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proceed Natl Acad Sci U S A. 1996;93(20):11213–11218. doi:10.1073/pnas.93.20.11213
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer′s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388(10062):2873–2884. doi:10.1016/S0140-6736(16)31275-2
   PubMed Web of Science ®Google Scholar
• Novak P, Zilka N, Zilkova M, et al. AADvac1, an active immunotherapy for Alzheimer′s disease and non Alzheimer tauopathies: an overview of preclinical and clinical development. J Prev Alzheimers Dis. 2018;6(1):1–7. doi:10.14283/jpad.2018.45
   Web of Science ®Google Scholar